Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:RNA 26 October 2025 - 27 October 2025

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis will acquire Avidity Biosciences for $12 billion in cash, offering $72 per share—a 46% premium over Avidity’s last close. Avidity’s stock, which ended Friday at $49.15, is expected to jump sharply when markets open. Novartis is targeting Avidity’s RNA therapies for rare muscle diseases, including a lead drug nearing FDA submission. The deal was announced Sunday, Oct. 26, 2025.
26 October 2025
····
Go toTop